Clinical trial Checkmate 142
CA209-142 A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations, in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and non-MSI-H Colon Cancer. Checkmate 142
Cancers | |
---|---|
Organ | Colon |
Trial status | Trial closed for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 2 |
Academic trial | Non |
Sponsor | BMS - Bristol Myers Squibb int. |
EudraCT Identifier | 2013-003939-30 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02060188 |
Inclusion criteria | metastatic RECIST 1.1 |
Last update |